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Therapeutic targetProteins with long polyglutamine repeats form a complex with glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH), which enhances aggregation and cytotoxicity in models of Huntington disease.
The aim of this study was to develop a novel assay for the screening of anti-aggregation compounds
with a focus on the aggregation-promoting capacity of GAPDH. The assay includes a pure Q58 poly-
glutamine fragment, GAPDH, and a transglutaminase that links the two proteins. The feasibility of
the new assay was veriﬁed using two GAPDH binders, hydroxynonenal and ()deprenyl, and the
benzothiazole derivative PGL-135 which exhibits anti-aggregation effect. All three substances were
shown to reduce aggregation and cytotoxicity in the cell and in the ﬂy model of Spinocerebellar
ataxia.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Polyglutamine pathologies constitute a group of diseases stem-
ming from a mutation that leads to the appearance of long gluta-
mine repeats, polyQ, in huntingtin and other cellular proteins [1].
Mutant polypeptides form cytotoxic oligomers and aggregates that
disturb physiology of nerve cells, leading to their dysfunction and
ultimately death [2,3]. Molecular organization of polyQ aggregates
is still elusive: according to one of the hypotheses, polyQ ﬁbrils cancross-link with other cellular polypeptides possessing lysine resi-
dues with free e-amino groups; the reaction is catalyzed by tissue
transglutaminase (tTG). Interestingly, the inhibitor of tTG cysta-
mine was shown to extend survival, reduce tremor and abnormal
movements, and ameliorate weight loss in transgenic mice
expressing mutant huntingtin [4]. One of the lysine donors was
found to be glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
[5,6]. The enzyme forms a tight complex with the mutant hunting-
tin in SK-N-SH neuroblastoma cells. Importantly, the aggregation
of the complex was prevented by anti-GAPDH siRNA as well as
by the substance with an afﬁnity to the enzyme molecule [7]. In
addition to proteins with long polyQ tracts, GAPDH forms com-
plexes with A-beta amyloid [8], mutant alpha-synuclein [9] and
mutant SOD1 [10].
To date, the simplest test systems for the high-throughput
screening are based on the aggregation of pure mutant huntingtin
or other polyQ-containing polypeptides. Mixtures of a pathogenic
protein with tested compounds are incubated in the wells of a spe-
cial 96-well manifold. After the addition of sodium dodecyl sulfate
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membrane is stained with anti-polyQ antibodies according to the
standard procedure of the enzyme-linked dot assay [11,12].
Since GAPDH was shown to strengthen polyQ-mediated aggre-
gation, the current study aims to present a new assay for the
screening of anti-aggregation substances targeting both polyQ-
containing protein and the enzyme. To test the assay, we chose
four chemicals having an afﬁnity to GAPDH or capable of prevent-
ing the formation of polyQ aggregates. ()Deprenyl (DEP) whose
tricyclic analogue CGP3466 (N-methyl-N-propargyl-10-amino-
methyl-dibenzoloksepin) can bind GAPDH in cells of various types
and block the intranuclear transport of GAPDH, which is ﬁrmly
attributed to apoptosis [13,14,7]. Another substance, hydroxynon-
enal (HNE), speciﬁcally binds GAPDH and prevents the interaction
of the enzyme with NAD+ [15]. The derivative of benzothiazole,
PGL-135 (PGL), demonstrated therapeutic effects in animal and cell
models of Huntington disease (HD) [16,17]. The last drug, N-phen-
oxyacetyl-L-cysteine (NPC), was found to interact with the active
site of GAPDH [18].
2. Materials and methods
2.1. Proteins
Recombinant exon 1 of huntingtin containing 58 (mutant form)
or 23 (wild type) glutamine resides, were expressed in Escherichia
coli cells, transformed with pGEX-2TK-httQ58 or pGEX-2TK-httQ23
plasmids generously provided by Dr. J. Wang (Massachusetts
General Hospital, Boston, USA). Since both constructs contained
glutathione-S-transferase (GST) tag, the proteins were puriﬁed
with the aid of Glutathione-Sepharose (GE Health Care, UK).
GAPDH was isolated from rabbit muscle as previously described;
its activity constituted 80 lmol NADH/min per mg of protein
[19]. tTG from guinea pig liver was purchased from Sigma–Aldrich
(USA).
2.2. Design of aggregation assay
The assay mixture contained 0.1 mg/ml of Q58-GST or Q23-GST,
0.1 mg/ml of GAPDH, and 0.005 mg/ml of tTG dissolved in phos-
phate buffer saline (PBS). Aggregate formation was initiated by
the addition of thrombin (1 unit per mg of peptide) (Sigma–
Aldrich, USA) that cleaves the link between the polyQ and GST.
The solution was incubated for 48 h at 37 C and then analyzed
using the ﬁlter trap assay. The samples of aggregating complexes
were mixed with 2% sodium dodecyl sulfate (SDS) and subjected
to ultraﬁltration with the use of a dot-blotting manifold (BioRad,
USA). The resulting membrane was incubated with the antibodies
against either polyQ (MAB1574, Millipore, Germany) or GAPDH
(6C5, Abcam, UK), and subsequently with secondary antibodies
conjugated with peroxidase; visualization of the dots was per-
formed using the chemiluminescence protocol. Dot intensity was
measured with the help of TotalLab Quant software.
2.3. Atomic force microscopy and dynamic light scattering
The samples of protein mixtures prepared as described above
were placed on glass supports, dried, and analyzed with the aid
of Ntegra Aura microscope (NT-MDT, Russia). The studies were
conducted at the Resource Center of Microscopy and Microanaly-
sis, St. Petersburg State University.
For the dynamic light scattering (DLS) study, mixtures contain-
ing 0.1 mg/ml of Q58-GST or Q23-GST, 0.1 mg/ml of GAPDH, and
0.005 mg/ml of tTG (Sigma–Aldrich, USA) in PBS were mixed with
thrombin (see previous section) and analyzed with the use of a
Zetasizer NanoZS (Malvern, UK).2.4. Drug afﬁnity responsive target stability (DARTS)
For DARTS assay, we use the protocol of Lomenick et al. [20]
with some modiﬁcations: instead of the pure protease, we used
trypsin immobilized on agarose (Sigma–Aldrich, USA). Before pro-
teolysis, GAPDH (5 lg in 20 ll) was incubated with binders at 4 C
for 1 h in a solution containing 50 mM Tris HCl, pH 8.0, 50 mM
NaCl, and 10 mM CaCl2. Then we added 2 ll of the trypsin-agarose
to each sample and incubated for 20 min at room temperature. The
gel was separated by centrifugation, and the supernatant was ana-
lyzed by immunoblotting using 6C5 anti-GAPDH antibodies.
2.5. Electrophoresis and Western blotting
Electrophoresis of proteins was performed in 12.5% polyacryl-
amide gel according to the standard protocol [21]. Protein bands
were transferred onto a PVDF membrane, 0.45 lm pore size,
(Millipore Corporation, Germany) using TransBlot apparatus
(BioRad, USA). The membranes were stained by the antibodies
against GAPDH and polyQ as indicated in Section 2.2.
2.6. Cell culture
SK-N-SH human neuroblastoma cells were transfected with
Q25-EGFP and Q103-EGFP plasmids (a gift of Dr. D. Rubinsztein,
Cambridge University, UK) with the aid of Lipofectamine 2000
(Invitrogen, USA) according to the manufacturer instructions. 4 h
after transfection, we replaced the growth medium and added test
substances. Cells were analyzed 24 h after transfection. To deﬁne
aggregation capacity in Q103-EGFP-expressing cells incubated
with test compounds we calculated the ratio between number of
cells with diffuse EGFP staining and the total amount of transfected
cells. To measure of cells dyeing due to polyQ aggregation we ana-
lyzed lactate dehydrohenase (LDH) activity in cell medium using
CytoTox96 kit (ProMega, USA).
2.7. Drosophila ﬂies
To model ataxia-3 in Drosophila we expressed UAS-
HsapnMJD.tr-Q78 PVA construct driven by GAL4-elavC155 vector.
The ﬂies were kept on agar with dry yeast; the substances were
added every day to yeast at ﬁnal concentration of 100 lM. Twenty
days after the ﬁrst drug administration, ﬂy heads were ﬁxed,
embedded in parafﬁn, and 5 lm brain slices were stained with
hematoxylin/eosin (Bio Optica, Italy). The slices were examined
using Leica DM 2500 microscope. To estimate the extend of degen-
eration we calculated the ratio between area free of cells and total
area of the brain.
The efﬁciency of polyQ aggregation in ﬂy brain was measured
with the aid of ultraﬁltration; the samples were obtained from
brain tissue of ﬂies 13–15 days after the beginning of the therapy.
The membrane was stained with anti-polyQ antibodies.
2.8. Statistical analysis
Statistical analysis was performed using one-way ANOVA test
supplemented with the post hoc test. The results were considered
statistically signiﬁcant at P 6 0.05 (⁄).
3. Results
3.1. Novel assay for aggregation activity
Our recent data indicate that in addition to polyQ, two proteins
GAPDH and tTG contribute to the formation of aggregates in HD
cell model. Thus, besides the principal component of the novel
Fig. 1. GAPDH and tTG are important components of the polyglutamine aggregates. (A) Data of ultraﬁltration: mixture of pure polyQ (Q23, control and Q58 pathogenic
repeats; 0.1 mg/ml), GAPDH (0.1 mg/ml) and tTG (0.005 mg/ml) was placed in the wells of a dot blotting manifold, and after ﬁltration, the membrane was stained with the
anti-polyQ antibodies (left panel) or anti-GAPDH antibodies (right panel). (B) The intensity of dots after ultraﬁltration in A was estimated with the use of TotalLab Quant
software. (C) The protein mixture prepared as in (A) was subjected to atomic force microscopy. Upper panel – 2D image of the surface; middle panel – distribution of the
number of pixels as a function of height; lower panel – 3D-reconstruction of the aggregates. (D) Samples of the proteins or their mixtures were analyzed using the method of
dynamic light scattering immediately after preparation; vertical axis represents size of aggregates, horizontal axis shows time, min. Experiments were made in triplicates.
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Fig. 2. Small molecules that are capable of binding to GAPDH prevent polyQ
aggregation in the assay system. (A) Data of DARTS assay: the products of GAPDH
trypsinolysis in the presence of DEP, HNE, PGL-135 and NPC were subjected to
electrophoresis and immunoblotting using anti-GAPDH antibodies. (B) GAPDH
binders effect the extent of the aggregation of pure Q58 or Q58-GAPDH-tTG
complex in the dose-dependent manner (1–100 lM); data of ultraﬁltration. (C) The
intensity of dots after ultraﬁltration in B was estimated with the use of TotalLab
Quant software Experiments were made in triplicates.
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pure GAPDH and tTG. The three proteins were mixed in the ratio
shown to cause fast and reproducible formation of polyQ aggre-
gates (Suppl. Fig. 1). The mixtures were analyzed by ultraﬁltration
and immunostaining. It was found that GAPDH itself is able to form
aggregates, though the quantity of SDS-insoluble material was 2
times lower than when the enzyme was mixed with polyQ
(Fig. 1A and B, right panels). The Q58 protein fragment aggregated
too, whereas shorter fragment Q23 gave no noticeable spot on the
membrane (Fig. 1A left panel). The addition of GAPDH increased
the intensity of aggregation of the complex approximately 3-fold
as revealed by staining with anti-polyQ (Fig. 1A and B, left panels).
Addition of tTG to the protein mixture enhanced the aggregation
1.5–2-fold over the value for the complex without the enzyme
(Fig. 1A and B).
To estimate the degree of aggregation of the polyQ complex
with GAPDH and tTG, we used atomic force microscopy (AFM).
The data of AFM demonstrated that the Q23 fragment gave no
aggregates, whereas the Q58 fragment produced amorphousstructures with the modal size of 8–10 nm (Fig. 1C). Pure GAPDH
also formed amorphous particles, whose size did not exceed
100 nm. The addition of GAPDH and tTG to the polyQ increased
the size of aggregates up to 120 and 200 nm, respectively
(Fig. 1C, middle and lower panels).
Next, we measured the rate of aggregation of Q58 fragment
mixed with GAPDH and tTG. The samples were analyzed by DLS,
and pure proteins or their mixtures were investigated immediately
after the mixing. Two hours after the initiation of the reaction, the
average size of aggregates of GAPDH with Q58 was 3-fold higher
than that of the polyglutamine alone (Fig. 1D). tTG was found to
enhance the process even more, proving the pivotal role of the
enzyme in cross-linking of the two aggregating proteins.
3.2. Selection of GAPDH-binding compounds
To prove the proper function of the assay, we chose a few
potential binders or regulators of polyQ-GAPDH aggregating
assembly (see Section 1 for details). To evaluate their ability to
bind to GAPDH, we used DARTS assay. The enzyme digestion prod-
ucts were subjected to electrophoresis and the peptide bands were
blotted and stained with the anti-GAPDH antibodies. It was found
that three of four substances, DEP, HNE and PGL, protected the
enzyme molecule from the cleavage, as seen by the preservation
of the initial band of 37 kDa on the blot (Fig. 2A). The concentration
of the substances at which they protected GAPDH was 10 lM; at
lower concentration, they were ineffective. NPC did not affect the
proteolysis of GAPDH: the enzyme band disappeared even in the
presence of 100 lM NPC in proteolysis mixture.
Next, we checked whether the selected substances could reduce
aggregation of the pure polyQ and polyQ-GAPDH–tTG complex. In
these experiments, the compound of interest was added to the
incubation mixture that was subjected to ultraﬁltration. Since the
membrane was stained with the antibodies to GAPDH and polyQ,
we could estimate the contribution of both proteins to the aggrega-
tion. It is important that signiﬁcantly inhibits aggregation of pure
Q58 (without GAPDH and tTG) only PGL (Fig. 2B, left panel), but
all substances inhibited the accumulation of SDS-insoluble mate-
rial in the polyQ-GAPDH–tTG case (Fig. 2B, central and right panels,
C, central and lower panel). The most effective was DEP and PGL
that prevented aggregation at the concentration of 1 lM in 2
times; two other inhibitors demonstrated anti-aggregating effect
at the level of 10 lM. In all cases, the amount of material in the
SDS-insoluble fraction was reduced to GAPDH and polyQ staining
patterns, suggesting that the particular target for the compounds
is GAPDH (Fig. 2B and C).
3.3. Effects of GAPDH binders in HD and ataxia-3 models
The next step was to test the substances chosen using SK-N-SH
neuroblastoma cells overexpressing Q103 fragment of the hunting-
tin gene. Cells were incubated with a tested drug for 24 h and their
lysates were subjected to ultraﬁltration as in 3.1. The maximal
inhibition of Q103 aggregation was achieved with DEP and PGL
that was active even at the concentration of 100 nM. NPC and
HNE demonstrated a lower degree of inhibition (Fig. 3A and B).
To prove the anti-aggregation effect of the compounds, we
employed Q103-EGFP-expressing cells that were divided in two
groups: the cells with bright green spots of the aggregates and cells
with diffused Q103-EGFP (Fig. 3C). The latter portion was related to
the total quantity of transfected cells in order to measure the
amount of ‘‘recovered’’ cells. It was found that the 24-h incubation
with DEP, PGL and HNE hampered the formation of intracellular
aggregates, and this inhibition occurred in the dose-dependent
manner (Fig. 3D). Notably, when these substances were employed
in the concentration of 1000 nM, the fraction of the cells contained
Fig. 3. Approval of the therapeutic potential of GAPDH binders in HD cell model. (A) SK-N-SH human neuroblastoma cells expressing Q103-EGFP were treated with GAPDH
binders for 24 h, lyzed, and the lysates were subjected to ultraﬁltration; the membrane was stained with anti-polyQ antibodies (see Section 2 for details). (B) The intensity of
dots after ultraﬁltration in A was estimated with the use of TotalLab Quant software. (C) Fluorescent images illustrate the protective effect of test compounds. (D) Estimation
of the share of cells containing no Q103 aggregates relative to the total amount of transfected SK-N-SH cells. Minimum 1000 cells were counted for each plot. (E) Estimation of
the viability of SK-N-SH cells expressing Q103 and treated with GAPDH binders (DEP, HNE, PGL-135 and NPC); the data of LDH test are presented. Experiments were made in
triplicates.
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mate the effect of the four compounds on the survival of model
cells, we analyzed LDH concentration. Overexpression of Q103
reduced the cell survival by 40–45%, and the vehicle (dimethylsulf-
oxide) had no effect on cell mortality (Fig. 3E). The incubation of
the cells with 100 nM or 1000 nM DEP and PGL enhanced the via-
bility by 15% and 20%, respectively. Similarly, but to the lower
extent, HNE rescued cells from polyQ-mediated cell death. Both
substances were most effective when administered in concentra-
tion of 1000 nM: they increased cell survival by 14% and 11%,
respectively (Fig. 3E). NPC had a few protective effect (about
5–7%) in 1000 nM concentration on the polyQ-expressing cells.
Importantly, none of the above compounds had any cytotoxiceffect in the range of concentrations employed of 10–1000 nM
(data not shown).
To prove anti-degenerative effect of the compounds selected,
we used Drosophila model of SCA-3. The drugs were administered
to ﬂies expressing 78Q ataxin-3 sequence in brain, we analyzed
aggregation of ataxin-3 in transgenic Drosophila model. So we
found that DEP, PGL and HNE reduced polyQ aggregation by
40–70% (Fig. 4A and B). The neurodegeneration was estimated as
the share of empty, cell-free area of the whole brain square on par-
afﬁn slices. We found that 78Q expression in Drosophila caused the
loss of neuronal tissue (Fig. 4C). Two substances, DEP and PGL,
were found to reduce empty area by 40%, and the vehicle (DMSO),
HNE and NPC had no protective effect (Fig. 4D).
Fig. 4. Test compounds reduce neurodegeneration in the brain of ataxia transgenic
ﬂies. (A) DEP, PGL and HNE signiﬁcantly decrease the amount of polyQ-containing
aggregates in ataxia-3 transgenic ﬂies; DMSO denotes vehicle. Data of ultraﬁltration
are presented. (B) The intensity of dots after ultraﬁltration in A was estimated with
the use of TotalLab Quant software. (C) Typical images of hematoxylin-eosin
staining of brain slices obtained from ﬂies lived on yeast alone or yeast with DMSO,
DEP, PGL, HNE. Arrows indicate lost areas in ﬂies’ brain. (D) Areas of neuronal loss in
brains fed with yeast alone or yeast with DMSO, DEP, PGL, HNE and NPC were
calculated; see text for details. Experiments were made in triplicates.
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The formation of cytotoxic oligomers and aggregates of mutant
huntingtin with abnormally long polyglutamine tracts appears to
be a major cause of massive death of striatum neurons in patients
with HD, making the insoluble protein complexes relevant targets
for the drug therapy. A few assays offered to date for the screening
of compounds with anti-aggregation activity are based on their
effect on polyQ aggregation [11,12]. Since our recent data convince
that other cellular polypeptides, particularly GAPDH, can form
complex with the mutant huntingtin and enhance its cytotoxicity
[7] we decided to advance the assay system using in addition to
polyQ pure GAPDH and tTG. The data of ultraﬁltration showed that
these two enzymes increased 10–15-fold the amount of SDS-insol-
uble material retarded by the membrane (Fig. 1A). Interestingly,
GAPDH alone was shown to form aggregates (Fig. 1A and C). The
data of DLS show that GAPDH in solution consists of tetramers of
about 8 nm [22]. We suggest that at low concentration (<0.1 mg/
ml) the enzyme dissociates into dimers, giving rise to aggregates.
It is generally believed that GAPDH can exhibit dimerization and
aggregation when responding to a variety of cellular stressors from
reactive oxygen species to polypeptides with a wrong conforma-
tion [23,24]. Both native tetramers and inactive forms of GAPDH
could be implicated in co-aggregation with polyQ, providing the
3–6-fold increase in the aggregation capacity when GAPDH was
added to Q58 (Fig. 1). With the addition of tTG, the aggregation
increased even more, proving our recent observation that the
enzyme is necessary for the strengthening polyQ-GAPDH or
mutant SOD1-GAPDH complexes [25]. The results of the ﬁlter trap
assay were conﬁrmed by the data of atomic force microscopy,
according to which the size of Q58 structures was approximately
10 nm; these data well correspond to results obtained by other
groups [26,27]. The addition of GAPDH enhanced the size of the
complexes up to 100 nm, and tTG increased this value 1.5-fold
(Fig. 1C). The important role of tTG in polyQ-GAPDH aggregation
was further supported by the data of dynamic light scattering. Itwas found that the active phase of the complex assembly takes
1 h, however, the addition of tTG extends this phase to 2 h; e.g.,
the enzyme affects both the kinetics and the intensity of polyQ-
GAPDH aggregation (Fig. 1D). Clearly, each protein component
plays a particular role in the pathogenic structure, and the pre-
sented assay system seems to imitate in vivo aggregating polyQ-
based complexes more profoundly than that with polyQ alone.
To verify the assay system, we chose DEP that is known to inhi-
bit polyQ aggregation in HD model [7], HNE, the binder of GAPDH
[28], and PGL found to reduce polyQ aggregation [16]. NPC shown
to recognize reactive cysteines on GAPDH molecule [18] was also
included in the list. To check the binding capacity of the four com-
pounds, we employed DARTS as the approach with the sensitivity
of nanomolar level [29]. It was found that DEP and to a lesser
extent HNE protected GAPDH molecule from the cleavage
(Fig. 2A). Unexpectedly, PGL also enhanced the resistance of GAP-
DH to trypsin; this result and demonstration of PGL binding to pol-
yQ [17,30] show that the effects of this benzothiazole derivative on
HD models need more detailed investigation.
The ability of the selected compounds to interact with GAPDH
was linked to their anti-aggregation effect. To check this, we
employed the assay system and found that DEP exhibited maximal
effect on the aggregation, which was noticeable at the concentra-
tion of 1 lM, see Fig. 2B. These values of critical concentration
are lower than those obtained for the compounds with anti-aggre-
gation activity in the assay system with pure polyQ (Fig. 2B). Thus,
despite the difference in components, our test system appears to
be more sensitive than analogues described in articles [11,12].
The principal advantage of the novel assay is that it better imitates
real conditions of the aggregation process in pathogenic cells asso-
ciated with the sequestration of different proteins including GAP-
DH and tTG [2].
To prove the therapeutic potential of the selected compounds,
we employed HD cell model based on SK-N-SH cells overexpress-
ing Q103. Analyzing the extracts of cells treated with the selected
compounds, we found that the amount of SDS-insoluble and
retarded on the membrane material was reduced by DEP and to
a lesser extent by PGL and HNE suggesting that these substances
inhibit polyQ aggregation not only ex vivo, but also in vitro
(Fig. 3A and B). It is noteworthy that the minimal concentration
of DEP that caused the effect was 10 nM, while the effective con-
centration of Congo Red, the inhibitor of polyQ aggregation, in sim-
ilar HD model also analyzed with the aid of ultraﬁltration was
found to be much higher, 3–30 lM [30]. We found that DEP, PGL
and HNE in concentration of 100 nM efﬁciently increased the con-
tent of the cells with diffusely distributed Q103-EGFP, suggesting
that the anti-aggregation effect of the above substances reduces
the size of the aggregates and their total content (Fig. 3C). The most
striking evidence of the therapeutic effect of selected compounds
came when we assayed the effect of the tested compounds on
the cells affected by polyQ aggregation. DEP was found to exert
maximal protective effect: after the incubation with 100 nM DEP,
the cell survival increased by 25% (Fig. 3C). Using ﬂy model of
SCA-3, we proved that DEP and PGL, possessed protective activity
in vitro too (Fig. 4). Thus, the substances preventing the aggrega-
tion of the polyQ-GAPDH–tTG complex as proved by the novel
assay system actively protect cells imitating HD. Since GAPDH
and tTG are implicated in a variety of neurological disorders, we
believe that the novel assay system can be adjusted and applied
for the screening of new substances for the therapy of the
described above pathologies.
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